Serum chitotriosidase levels in cancer patients undergoing high dose chemotherapy and stem cell transplantation

M. Ozturk, E. Özkan, V. Kesik, S. Ozaydın, O. Babacan, H. Yaman, E.O. Akgül, S. Kılıc, F. Arpaci, A. Ozet, I. Kurt, S. Demirbas, E. Arslan, D. Tok

Department of Medical Oncology, Gulhane Military Medical Academy, Ankara, Turkey. oguzhanbabacan@yahoo.com

---

• Obstetrics

OBJECTIVE: Human chitotriosidase (ChT) is an active chitinase expressed by activated phagocytes. Increased ChT activity has been reported in systemic Candida albicans infections and in Gram-negative and Gram-positive bacterial infections, indicating that an increase in ChT activity reflects phagocyte activation. The aim of this study was to determine the changes in serum ChT activity in patients who underwent high dose chemotherapy (HDC) and stem cell transplantation (SCT), who are at an increased risk for fungal and bacterial infections due to depression of the immune system during the neutropenic period.

PATIENTS AND METHODS: A total of 55 SCT patients were included in the study. Serum ChT activity was determined before the initiation of HDC and during the neutropenic period after hematopoietic stem cell reinfusion on post-transplant first, fifth and tenth days.

RESULTS: Chitotriosidase levels before transplantation were significantly lower than the results at first, fifth and tenth days post-hematopoietic stem cell reinfusion.

CONCLUSIONS: Although the number of neutrophils was low, ChT enzyme activity was high in newly produced granules of neutrophils. Chitotriosidase may be supplemented as a drug for preventing and treating infections in the near future.

Free PDF Download